Publications in collaboration with researchers from Instituto de Investigación Sanitaria La Fe (17)

2024

  1. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

    Blood, Vol. 143, Núm. 18, pp. 1807-1815

  2. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

    Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851

  3. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

2023

  1. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

    Blood Cancer Journal, Vol. 13, Núm. 1

  2. IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients

    Journal of Fungi, Vol. 9, Núm. 6

  3. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry

    Cancers, Vol. 15, Núm. 2

2022

  1. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

    Blood Advances, Vol. 6, Núm. 4, pp. 1278-1295

2021

  1. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

    PLoS ONE, Vol. 16, Núm. 9 September

2020

  1. Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis

    Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158

  2. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

  3. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 12, pp. 2237-2244

2019

  1. Identification of 58 mutations (26 Novel) in 94 of 109 symptomatic Spanish probands with protein C deficiency

    Thrombosis and Haemostasis, Vol. 119, Núm. 9, pp. 1409-1418

  2. Involvement of antifactor VIII autoantibodies specificity in the outcome of inhibitor eradication therapies in acquired hemophilia a patients

    Blood Coagulation and Fibrinolysis, Vol. 30, Núm. 3, pp. 127-132

2018

  1. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia

    British Journal of Haematology

  2. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

    Blood Cancer Journal, Vol. 8, Núm. 10

  3. Prognostic risk models for transplant decision-making in myelofibrosis

    Annals of Hematology, Vol. 97, Núm. 5, pp. 813-820

2017

  1. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis

    European Journal of Haematology, Vol. 98, Núm. 4, pp. 407-414